Skip to content

In Vivo Optical Spectroscopy Monitoring in a New Model of Muscular Compartment Syndrome

In Vivo Optical Spectroscopy Monitoring in a New Model of Muscular Compartment Syndrome.

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01452425
Enrollment
10
Registered
2011-10-14
Start date
2011-10-31
Completion date
2011-12-31
Last updated
2014-12-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Human Volunteers

Keywords

Human volunteers

Brief summary

Muscular compartment syndrome (MCS) is consecutive to an increase in intramuscular compartment pressures, and is a rare but serious postoperative complication. The INVOS (In Vivo Optical Spectroscopy) monitors tissular oxygenation continuously and non-invasively. The objective is to develop a model mimicking the physiopathology of MCS to assess the interest of the INVOS in this case.

Detailed description

After inflation of a tourniquet (pressure equal to the mean arterial pressure, we will obtain a model of slight venous congestion and arterial hypoperfusion. A comparison will be made between INVOS monitoring, sensory deficits, pain, electromyography and invasive pressure.

Interventions

DEVICETourniquet

Inflation of a tourniquet (pressure equal to the mean arterial pressure) obtaining a model of slight venous congestion and arterial hypoperfusion

DEVICEINVOS assessment

Near Infraread spectroscopy, non invasive

DEVICEEMG assessment

Electromyography, non invasive

Sponsors

Université Catholique de Louvain
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
18 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy volunteers * \>18yr * Informed consent * Male

Exclusion criteria

* Neuropathies * Vascular pathology * Actual pain * Anti-platelet or anticoagulant therapy * Ipsilateral history of fracture

Design outcomes

Primary

MeasureTime frameDescription
Comparison Between INVOS Monitoring and Electromyography45 minutesA comparison will be made between the INVOS monitoring and non invasive (transcutaneous) EMG monitoring (AP Block), to determine the accuracy of the INVOS monitoring to predict AP block. Measures were: \[mean (SD)\] INVOS (in %) value at baseline and at the time of the block
Intracompartmental Pressure (ICP)45 minutes\[mean (SD)\] ICP (in mmHg), value at baseline and at the time of the block

Countries

Belgium

Participant flow

Participants by arm

ArmCount
Tourniquet
No adverse event
10
Total10

Baseline characteristics

CharacteristicTourniquet
Age, Customized
age
33 years
STANDARD_DEVIATION 4
Sex: Female, Male
Female
0 Participants
Sex: Female, Male
Male
10 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
0 / 10
serious
Total, serious adverse events
0 / 10

Outcome results

Primary

Comparison Between INVOS Monitoring and Electromyography

A comparison will be made between the INVOS monitoring and non invasive (transcutaneous) EMG monitoring (AP Block), to determine the accuracy of the INVOS monitoring to predict AP block. Measures were: \[mean (SD)\] INVOS (in %) value at baseline and at the time of the block

Time frame: 45 minutes

ArmMeasureGroupValue (MEAN)Dispersion
TourniquetComparison Between INVOS Monitoring and ElectromyographyINVOS (Baseline)73 % of StcO2Standard Deviation 9
TourniquetComparison Between INVOS Monitoring and ElectromyographyINVOS (At time of the block)46 % of StcO2Standard Deviation 11
Primary

Intracompartmental Pressure (ICP)

\[mean (SD)\] ICP (in mmHg), value at baseline and at the time of the block

Time frame: 45 minutes

ArmMeasureGroupValue (MEAN)Dispersion
TourniquetIntracompartmental Pressure (ICP)ICP (Baseline)17 mmHgStandard Deviation 9
TourniquetIntracompartmental Pressure (ICP)ICP (At time of the block)70 mmHgStandard Deviation 6

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026